The Pharma Data

NOVEMBER 9, 2021

” The findings not only answer important questions about key mechanisms of the complex SARS-CoV-2 virus, Elias said, but also have direct implications for the development of therapeutics to control the viral infection. What’s more, chitinase 3-like-1 augments SARS CoV-2 infection.”

Small Molecule 52

Small Molecule Virus Molecular Biology Disease 52

PerkinElmer

MAY 28, 2020

Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus. Additionally, procuring the live virus for an evaluation assay is very difficult and labor intensive. Such high safety measures, although essential, can extend the timing of the development of a vaccine.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

SEPTEMBER 29, 2020

It is a synthetic small molecule that would be self-administered via nasal spray, taken once or twice a week for the prevention of COVID-19. By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus,” said Christophe Demaison, managing director of Ena Respiratory. “If

Small Molecule 52

Small Molecule Immune Response Virus Treatment 52

PerkinElmer

JANUARY 21, 2021

It is particularly prevalent on cells that line the air sacs in lungs, hence the rampaging respiratory effects we’ve come to associate with the virus. AlphaLISA assay technology can be used in small molecule discovery but can also be applied to large molecule discovery, including biologics, vaccines and cell-based therapies.

Treatment 52

Treatment Small Molecule Drugs Virus 52

The Pharma Data

SEPTEMBER 28, 2020

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus,” explained Dr Christophe Demaison, Managing Director at Ena Respiratory.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. This cleaning, annotation, and characterization work is all performed computationally. This cleaning, annotation, and characterization work is all performed computationally.

DNA 93

DNA Laboratories Hospitals Virus 93

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

In particular, Editas is known to be exploring tunable CRISPR-Cas9 systems for therapies has developed self-inactivating Cas9 adeno-associated virus vectors. Most Read Today. Source link.

Research 52

Research RNA Molecular Biology Small Molecule 52

Drug Target Review

DECEMBER 7, 2023

Specific RNA structure The scientists and their collaborators from Sean Brady’s Laboratory of Genetically Encoded Small Molecules focused on the CBASS system in Staphylococcus schleiferi , a bacterium often located in the mouth of dogs and cats. He continued: “CBASS cyclases look a lot like cGAS, so they have to be sensing something.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The ChEMBL-og

SEPTEMBER 1, 2021

For example, queries may be performed to extract high level pathogen data such as all bioactivity data for small molecules screened against bacterial targets (example below) or more specific subsets focused on gram-positive pathogens or on a single bacterial species.

Cell Based Assays 52

Cell Based Assays Screening Hits Small Molecule Virus 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

Molecular Design

AUGUST 9, 2020

There are three general approaches to directly tackle a virus such as SARS-CoV-2 with a small molecule drug (or chemical agent). First, destroy the virus before it even sees a host cell and this is the objective of hand-washing and disinfection of surfaces.

Drugs 52

Drugs Virus Small Molecule Treatment 52

The Pharma Data

JANUARY 31, 2021

Convergent has identified certain small molecules that bind to PSMA, but at a different epitope than does CONV 01-?, Importantly, Convergent identified small molecules, with a current focus on the molecule PSMA I&T, that have different biodistributions in the body than does CONV 01-? .

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

The Pharma Data

AUGUST 18, 2020

CARE will focus on three strategic pillars to achieve therapeutic breakthroughs against SARS-CoV-2 (the virus that causes COVID-19 disease) and other coronavirus threats: Drug repositioning and repurposing. Small molecule discovery. Virus-neutralizing antibody discovery.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. On top of this, treated individuals are susceptible to reinfection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. About TNX-1800.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Codon

DECEMBER 12, 2024

A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine.

DNA 102

DNA RNA Vaccine Virus 102

Advarra

JANUARY 11, 2024

Immunomodulatory Proteins Immunomodulators are molecules influencing the pathways regulating the body’s immune system activities. After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

JANUARY 13, 2021

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

New Drug Approvals

JANUARY 31, 2024

BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

NIH Director's Blog: Drug Discovery

MARCH 8, 2016

Golub and colleagues produced the library by using a virus to insert a distinct DNA barcode, just 24 nucleotides long, stably into the genomes of each genetically distinct tumor cell line. With PRISM, it’s now feasible to screen entire small molecule libraries across large panels of cancer cell lines.

DNA 52

DNA Drugs Small Molecule FDA Approval 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. Antibodies are proteins that guard against foreign substances that enter our bodies,such as bacteria, fungi, viruses and toxins.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules. KAN-101 is in a randomized, double-blind, placebo-controlled Phase I study, Assessment of KAN-101 in Celiac Disease. Patient Recruitment.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 6, 2021

Bio-CDMO business offers services for biopharmaceuticals and small molecule pharmaceuticals. Going forward, Fujifilm will continue to contribute to the healthcare industry by providing a stable supply of high quality pharmaceuticals. * Overview of New Site. 1. Location.

Packaging 52

Packaging Small Molecule Production FDA Approval 52

Drug Target Review

JULY 11, 2023

B-cell white blood cell, type of lymphocyte produce antibody molecules. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company. B cell is humoral immunity component of the immune system producing antibodies, protect against pathogens: bacteria, viruses. “We

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

JANUARY 19, 2021

Syros is redefining the power of small molecules to control the expression of genes. About Syros Pharmaceuticals. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

DECEMBER 23, 2020

While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s This is proving very difficult, however, for the ever-expanding group of people dealing with the chronic and debilitating symptoms of what is commonly being called “Long Haul COVID” or “Long COVID.”.

Clinical Trials 52

Clinical Trials FDA Small Molecule Trials 52

The Pharma Data

JANUARY 18, 2021

Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir ® ”).

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

SEPTEMBER 12, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Auxora is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

Codon

JUNE 11, 2024

Small molecules can randomly transit through the pore and create disruptions, and the polymerase ratchet mechanism is imperfect, occasionally causing DNA to temporarily reverse direction through the pore. This problem was easily resolved by engineering a version of MspA without that particular amino acid.

DNA 79

DNA Engineering RNA Small Molecule 79

New Drug Approvals

APRIL 18, 2023

[H]Cl.NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3 AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. AMD-070 targets the CXCR4 receptor on HIV and prevents the virus from entering and infecting healthy cells. Skerlj RT, et al.

Clinical Trials 52

Clinical Trials Virus Small Molecule Trials 52

The Pharma Data

DECEMBER 5, 2020

About Syros Pharmaceuticals Syros is redefining the power of small molecules to control the expression of genes. The trial will also evaluate the triplet as a salvage therapy in patients who don’t respond to venetoclax and azacitidine. Syros expects to initiate the Phase 2 trial in the second half of 2021.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52